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INTRODUCTION 
Cholangiocarcinoma (CC) is an adenocarcinoma arising from 
epithelial cells of varying locations within the biliary tree, and is 
the second most common primary liver tumor, accounting for ap-
proximately 10-15% of all hepatobiliary malignancies.1 This dis-
ease has a high prevalence in Southeast and Eastern Asia, includ-
ing Korea; during the period 2003-2005, the age-standardized 
incidence rates of intrahepatic CC and extrahepatic CC were re-
ported to be 6.9 and 5.2 out of 100,000 in Korea, respectively.2 
Sarcomatoid carcinoma is a rare tumor composed of mixed malig-
nant epithelial and mesenchymal cells, and it can occur in various 
organs including liver. The prevalence of sarcomatoid CC has been 
reported to be about 4.5% of surgical and autopsied cases.3 Most 
sarcomatoid CCs have been reported to have sarcomatous com-
ponent which show spindle cell or pleomorphic cell differentia-
tion.4 Furthermore, sarcomatoid CC with osteoclast-like giant 
cells, which morphologically resemble those found in giant cell tu-
mors of the bone is a very rare malignant liver tumor which was 
first reported as osteoclastoma-like giant cell tumor of the liver by 
Munoz et al. in 1980.5 To the best of our knowledge, sarcomatoid 
CC with osteoclast-like giant cells are extremely rare and only 5 
cases were reported in the literature so far.6 Here we report a 
case of sarcomatoid CC with osteoclast-like giant cells, which is 
associated with hepatolithiasis.
CASE SUMMARY
A 67-year-old woman was referred to our hospital for right up-
per quadrant abdominal pain for 3 weeks. She had no history of 
alcohol ingestion or smoking, and no remarkable medical history. 
A computed tomography scan was performed to evaluate the 
cause of abdominal pain, and revealed distal common bile duct 
stone or sludge with dilatation of the common bile duct and bilat-
eral intrahepatic ducts and a 6 cm-sized heterogeneous lobulated 
mass in the left lateral segment of the liver, suggestive of intrahe-
patic CC with multiple left intrahepatic duct stones (Fig. 1A, B). 
There was no definite evidence of hepatic artery or portal vein in-
vasion or intrahepatic metastasis. Initial laboratory findings 
showed normal liver function tests: aspartate aminotransferase 
16 IU/L, alanine aminotransferase 22 IU/L, total bilirubin 0.4 mg/
dL, direct bilirubin 0.1 mg/dL and elevated gamma-glutamyl trans-
peptidase 97 IU/L and alkaline phosphatase 151 IU/L. Tumor 
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marker tests revealed elevated carbohydrate antigen 19-9 (1598.0 
U/mL) and carcinoembryonic antigen (109.60 ng/mL) levels. Test-
ing for hepatitis B and hepatitis C virus were negative. Under the 
impression of mass-forming intrahepatic CC, she underwent a left 
lobectomy of the liver. 
PATHOLOGIC FINDINGS
On gross examination, the cut surface revealed a single, firm, 
whitish to tan mass (4.5×4.0 cm) with periductal infiltration 
around the dilated left intrahepatic duct. The duct lumen was dis-
tended to about 2 cm in diameter with 3 cm sized black stone im-
paction (Fig. 2). Microscopically, the tumor showed two distinct 
components; carcinomatous component and sarcomatous compo-
nent (Fig. 3A, 4A). In the carcinomatous component, the malig-
nant cells formed irregular papillae or fused glands in a prominent 
fibrous stroma, consistent with features of a typical well-to-mod-
erately differentiated adenocarcinoma. The columnar-to-cuboidal 
epithelial neoplastic cells had atypical nuclei with some prominent 
Figure 2. Gross finding. The representative cut surface reveals a single, firm, whitish to tan mass (4.5×4.0 cm) with periductal infiltration around the di-
lated left intrahepatic duct. The lumen of bile duct is distended up to 2 cm in diameter and impacted with pigment stone. 
Figure 1. Image finding. An axial CT image shows a 6cm-sized heterogeneous lobulated mass in the left lateral segment of the liver (A). Another CT 
image shows bilateral intrahepatic duct dilatation and multiple left intrahepatic duct stones, measuring 3 cm in the largest one (B). 
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nucleoli, slightly eosinophilic and granular cytoplasm, and some 
mitosis (Fig. 3B). In the sarcomatous component, there were pleo-
morphic cells and atypical spindle cells with vesicular nuclei and 
prominent nucleoli (Fig. 3C). The two components were intermin-
gled. In addition, there were many scattered osteoclast-like giant 
cells: large multinucleated giant cells containing 10-25 nuclei and 
about 150-200 µm in diameter (Fig. 4F). Perineural invasion and 
microvessel invasion were seen. In surrounding liver, hepatolithia-
sis with chronic proliferative cholangitis and microabscess forma-
tion was noted (Fig. 3D). The immunohistochemical staining re-
sults also demonstrated two distinct patterns. The carcinomatous 
portion was positive for cytokeratin 19 (Fig. 4B) and negative for 
vimentin. The sarcomatous portion was positive for vimentin (Fig. 
4E) and negative for cytokeratin 19. Both were negative for hepa-
tocyte antigen and alpha-fetoprotein. The osteoclast-like giant 
cells were positive for CD68 (PG-M1) (Fig. 4F). The immunohisto-
chemical staining with EMT-related markers, E-cadherin and uPAR 
was conducted. E-cadherin showed total loss in the sarcomatous 
portion and no loss in the carcinomatous portion (Fig. 4C). uPAR 
was positive in the sarcomatous portion and peritumoral stroma 
but negative in the carcinomatous portion (Fig. 4D). 
DISCUSSION 
Sarcomatoid CC is an extremely rare liver primary tumor, and its 
pathogenesis still remains unclear. Sarcomatous change may be 
explained by epithelial–mesenchymal transition (EMT), which re-
fers to the biologic process of epithelial phenotype changing to 
mesenchymal phenotype by undergoing multiple biochemical 
Figure 3. Microscopic finding. Carcinomatous component and sarcomatous component are intermingled (A. H-E, ×40). Carcinomatous component 
shows the features of typical well-to-moderately differentiated adenocarcinoma (B. H-E, ×200). Sarcomatous component is consisted with pleomor-
phic cells and atypical spindle cells (C. H-E, ×200). In surrounding liver, hepatolithiasis with chronic proliferative cholangitis and microabscess formation 
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changes including enhanced migratory capacity, invasiveness, ele-
vated resistance to apoptosis, and increased production of extra-
cellular matrix components. A hallmark of EMT is the loss of epi-
thelial characteristics such as a decrease in the expression of the 
cell adhesion molecule E-cadherin and acquisition of a mesenchy-
mal phenotype accompanied by increased expression of vimentin. 
Transforming growth factor β as well as transcription factors such 
as Twist, Snail, Slug, Sip1, ZEB1 and ZEB2 have a regulatory role 
in EMT.7 Also, increased uPAR expression has been implicated in 
the promotion of EMT in various cancers.8 Previous report about 
27 cases of sarcomatoid carcinoma originating from various or-
gans, mostly from gastrointestinal tract which included 4 cases of 
CCs demonstrated that most sarcomatoid carcinomas express 
EMT-related markers such as Twist1, Snail1, Slug, Sip1 and ZEB1.9 
Presenting case showed a positive expression for EMT-related 
markers: vimentin, uPAR, and loss of E-cadherin, suggesting of 
EMT. 
Another sarcomatoid carcinoma primarily occurring in the liver 
is sarcomatoid hepatocellular carcinoma (HCC), and 73 cases of 
sarcomatoid HCC have been reported in the English literature in 
the past 20 years.10 Preoperative anticancer treatment such as 
transcatheter arterial chemoembolization, radiofrequency ablation 
or percutaneous ethanol injection has been reported to be asso-
ciated with sarcomatous change in HCC.11 Sarcomatoid HCC 
without previous therapies was also reported, although there 
are only a few reports of such cases.12 The present patient 
with sarcomatoid CC had no history of preoperative treatment, 
therefore, preoperative treatment is not considered to be neces-
sary for the sarcomatoid change.
Interestingly, this case showed osteoclast-like giant cells in ad-
dition to spindle cells of sarcomatous component. Tumors that 
contain osteoclast-like giant cells have been reported in several 
sites, which include the pancreas, lung, thyroid gland, stomach, 
breast, uterus, kidney, soft tissue, salivary glands,13 and liver.14 Os-
teoclast-like giant cells which closely resemble those of giant cell 
tumors of bone may be derived from bone marrow monocytes as 
they express the monocytic/histiocytic marker, CD6815 and are 
negative for the epithelial markers. In this case, they were positive 
for CD68, and were negative for the epithelial marker, cytokeratin 
19. These findings support that osteoclast-like giant cells are not 
epithelial origin but monocytic/histiocytic origin.
This presenting case showed chronic cholangitis with hepatoli-
thiasis in the non-neoplastic liver. Clinically, hepatolithiasis is con-
sidered as a main cause of CC in Korea16 and approximately 10% 
Figure 4. Immunohistochemical finding. Microscopic feature of sarcomatoid cholangiocarcinoma shows intermingled carcinomatous and sarcoma-
tous component (A. H-E, x100). Carcinomatous component shows strong expression of cytokeratin 19, but sarcomatous component shows no expres-
sion of cytokeratin 19 (B. CK19, ×200). E-cadherin shows total loss in the sarcomatous portion and no loss in the carcinomatous portion (C. E-cadherin, 
×200). uPAR is positive in the sarcomatous portion but negative in the carcinomatous portion (D. uPAR, x200). Sarcomatous component shows diffuse 
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of patients with hepatolithiasis develop CC.17 Repeated episodes 
of cholangitis due to hepatolithiasis are considered to induce pro-
liferative epithelial changes and accelerate tumorigenesis.18
The prognosis of CC is generally unfavorable because of fre-
quent metastasis, low resectability rate and high incidence of re-
currence even after curative resection. The median survival is 27 
months, and 5-year survival was 31%.19 The outcome of sarcoma-
toid CC appears to be even worse than conventional CC without 
sarcomatous change.20 Previous reports have demonstrated that 
these tumors are consistently very aggressive because of intrahe-
patic metastasis and frequent widespread metastasis of sarcoma-
toid cells.3 Therefore, early detection and complete surgical resec-
tion might be the only chance to improve the patient’s outcome.21 
The present case had no intrahepatic metastasis or extrahepatic 
metastasis at the time of operation, and there was no evidence of 
cancer recurrence at 6 months after operation.
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